Transcript segment
Baric Transcribed Interview (Redacted), pp.84-85 · baric_ti:utt:00748
Page text: p.84, p.85 · original PDF
- Date
- 2026-04-10 09:00 (day precision)
- Type
- transcript segment · interview
- recipient
- Christina Salazar, Harry Kazenoff, David T. Lambeth III, William Henderson, Clark Ervin, Jake Greenberg
- speaker
- Ralph S. Baric
- Topics
- Vaccines
It's a lower probability virus. Okay. So
for a pan-coronavirus vaccine you have pan-coronavirus beta
coronavirus vaccines and alpha coronavirus vaccines. So
this is an alpha coronavirus. So the only thing that
people have really worked on extensively are pan-beta
coronavirus vaccines, focused heavily on SARS coronavirus
and MERS coronavirus. So I don't imagine that that would
be included in any pan-beta coronavirus vaccine.
Now, for pan-alpha coronavirus vaccines, the classic
human coronaviruses are 229E and LN63. SADS would be
something that you might want to consider. But the fact of
DC.Scheduling@LexitasLegal.com
the matter is that those viruses, in general, in Clade 1,
in alpha-coronavirus group have been much less well
studied. And so the threat potential and where that exists
really is a guess.